Since BGR’s inception, the firm’s health and life sciences practice has been a driving force in its growth. Clients large and small from the pharmaceutical and medical device industries, to the nursing home, physician, and hospital communities, depend on BGR for its distinctive knowledge of the health care policy and regulatory landscape. The firm’s health care lobbyists have played key roles in the debate over major health care legislation.
Health care today involves a complicated network of state and federal policy, ranging from product approvals and sales, to Medicaid and Medicare reimbursement policies. BGR’s lobbyists have navigated this complex course and earned a reputation of excellence and created an unrivaled health and life sciences practice.
To better serve our clients, we have established two working groups within our health and life sciences practice:
The FDA & Public Health Working Group
The FDA & Public Health Working Group, headed by Remy L. Brim, Ph.D., and John Stone, advises and represents a wide range of biopharmaceutical, medical technology, consumer product, and food companies, as well as trade associations, with legislative and regulatory policy matters pertaining to the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and other government entities with scientific and public health missions.
The Access & Reimbursement Working Group
The Access & Reimbursement Working Group, headed by Matt Hoffmann and Robb Walton, works with health care organizations such as provider groups and medical product manufacturers, as well as other leading companies and trade associations throughout our nation’s health care delivery system. The Access & Reimbursement team works on all policy matters pertaining to the Center for Medicare and Medicaid Service (CMS) as well as the state and federal commercial insurance marketplace. Additionally, this team works directly with CMS to provide client insights on how to ensure patient access to important treatments and services.